Clinical and surgical assistance in prostate cancer during the COVID-19 Pandemic: implementation of assistance protocols

Conclusions: Most of the biopsies should be delayed while AS is advised in those patients with low risk PCa. ADT allows us to defer definitive local treatment in many cases of intermediate and high risk PCa. In regard to metastatic and castration resistant PCa, combination therapies with abiraterone, apalutamide, darolutamide or enzalutamide could be considered. Chemotherapy, Radium-223 and immunotherapy are discouraged.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research